Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

2011

Nov-Dec 2011 edition

  • Status Update on the National Cardiovascular Prevention Guidelines
  • Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk
  • P&T Committee Formulary Action

Sep-Oct 2011 edition

  • New Oral Anticoagulant (Rivaroxaban [Xarelto])
  • New Antiplatelet (Ticagrelor [Brilinta])
  • Update on Dabigatran (Pradaxa) Safety and Use at UIMCC
  • What Methods are Available for Reversal of Dabigatran and Rivaroxaban?
  • P&T Committee Formulary Action

Jul-Aug 2011 edition

  • Drug Safety Concerns in Pediatric Patients
  • Safety data with pioglitazone and bladder cancer
  • New FDA Dosing Recommendations for Erythropoiesis-Stimulating Agents

May-Jun 2011 edition

  • Use of PPIs in noncritically ill patients—risk of gastrointestinal bleeding
  • Update on use of vitamin D—2011 guidelines from the Endocrine Society
  • Intravenous acetaminophen—use and efficacy in pediatric patients
  • P&T Committee Formulary Action

Mar-Apr 2011 edition

  • Food and Drug Administration 2010-2011 Drug Safety News
  • Drug Shortages: Impact, Etiology, and Effective Management
  • P&T Committee Formulary Action

Jan-Feb 2011 edition

  • New MRSA Treatment Guidelines from IDSA
  • What’s New in Atrial Fibrillation?
  • FDA Limits for Acetaminophen-containing Products
  • P&T Committee Formulary Action
Top